Andreas Wiggers Nielsen

Andreas Wiggers Nielsen

Auto-generated profile, based on publicly available information

Andreas Wiggers Nielsen

Department of Rheumatology, Aarhus University Hospital , Aarhus

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
ANAndreas Wiggers Nielsen
Andreas Wiggers Nielsen
LFLine Lier Frølund
Line Lier Frølund
CVChristoffer Våben
Christoffer Våben
ABAsta Roos Bonde
Asta Roos Bonde
LGLars Christian Gormsen
Lars Christian Gormsen
KKKresten Krarup Keller
Kresten Krarup Keller
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) can be concurrent diseases. We aimed to estimate the point-prevalence of concurrent GCA and PMR. Additionally, an incidence rate (IR) of GCA presenting after PMR diagnosis in patients was estimated. Two authors performed a systematic literature search, data extraction and risk of bias assessment independently. Studies assessing cohorts of patients presenting with both GCA and PMR were included. The outcomes were point-prevalence of concurrent GCA and PMR and IR for development of GCA after PMR diagnosis. A meta-analysis was performed to calculate a pooled prevalence of concurrent PMR and GCA. We identified 29 studies investigating concurrent GCA and PMR. Only two studies applied imaging systematically to diagnose GCA and none to diagnose PMR. GCA presenting after PMR diagnosis was assessed in 12 studies but imaging was not applied systematically. The point-prevalence of concurrent GCA present at PMR diagnosis ranged from 6%-66%. The pooled estimate of the point-prevalence from the meta-analysis was 22%. The point-prevalence of PMR present at GCA diagnosis ranged from 16%-65%. The pooled estimate of the point-prevalence from the meta-analysis was 42%. The IR ranged between 2-78 cases of GCA presenting after PMR per 1000 person-years. This review and meta-analysis support that concurrent GCA and PMR is frequently present at the time of diagnosis. Additionally, we present the current evidence of GCA presenting in patients after PMR diagnosis. These results emphasize the need for studies applying imaging modalities to diagnose GCA.

1 December 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
KKKresten Krarup Keller
Kresten Krarup Keller
CMChetan B Mukhtyar
Chetan B Mukhtyar
ANAndreas Wiggers Nielsen
Andreas Wiggers Nielsen
AHAndrea Katharina Hemmig
Andrea Katharina Hemmig
SMSarah Louise Mackie
Sarah Louise Mackie
CDChristian Dejaco
Christian Dejaco
Objective To develop international consensus-based recommendations for early referral of individuals with suspected polymyalgia rheumatica (PMR). Methods A task force including 29 rheumatologists/internists, 4 general practitioners, 4 patients and a healthcare professional emerged from the international giant cell arteritis and PMR study group. The task force supplied clinical questions, subsequently transformed into Population, Intervention, Comparator, Outcome format. A systematic literature review was conducted followed by online meetings to formulate and vote on final recommendations. Levels of evidence (LOE) (1–5 scale) and agreement (LOA) (0–10 scale) were evaluated. Results Two overarching principles and five recommendations were developed. LOE was 4–5 and LOA ranged between 8.5 and 9.7. The recommendations suggest that (1) each individual with suspected or recently diagnosed PMR should be considered for specialist evaluation, (2) before referring an individual with suspected PMR to specialist care, a thorough history and clinical examination should be performed and preferably complemented with urgent basic laboratory investigations, (3) individuals with suspected PMR with severe symptoms should be referred for specialist evaluation using rapid access strategies, (4) in individuals with suspected PMR who are referred via rapid access, the commencement of glucocorticoid therapy should be deferred until after specialist evaluation and (5) individuals diagnosed with PMR in specialist care with a good initial response to glucocorticoids and a low risk of glucocorticoid related adverse events can be managed in primary care. Conclusions These are the first international recommendations for referral of individuals with suspected PMR, which complement the European Alliance of Associations for Rheumatology/American College of Rheumatology management guidelines for established PMR.

2 April 2024 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ANAndreas Wiggers Nielsen
Andreas Wiggers Nielsen
IHIb Tønder Hansen
Ib Tønder Hansen
BNBerit Dalsgaard Nielsen
Berit Dalsgaard Nielsen
SKSøren Geill Kjær
Søren Geill Kjær
JBJesper Blegvad-Nissen
Jesper Blegvad-Nissen
KKKresten Krarup Keller
Kresten Krarup Keller
Purpose: 2-[18F]Fluoro-2-deoxy-D-glucose (FDG)–positron emission tomography (PET)/computed tomography (CT) has been suggested as an imaging modality to diagnose polymyalgia rheumatica (PMR). However, the applicability of FDG-PET/CT remains unclear, especially following glucocorticoid administration. This study aimed to investigate the diagnostic accuracy of FDG-PET/CT before and during prednisolone treatment, as well as following short-term prednisolone discontinuation. Methods: Treatment naïve suspected PMR patients were clinically diagnosed at baseline and subsequently had an FDG-PET/CT performed. Patients diagnosed with PMR were administered prednisolone following the first FDG-PET/CT and had a second FDG-PET/CT performed after 8 weeks of treatment. Subsequently, prednisolone was tapered with short-term discontinuation at week 9 followed by a third FDG-PET/CT at week 10. An FDG-PET/CT classification of PMR/non-PMR was applied, utilizing both the validated Leuven score and a dichotomous PMR score. The final diagnosis was based on clinical follow-up after 1 year. Results: A total of 68 and 27 patients received a final clinical diagnosis of PMR or non-PMR. A baseline FDG-PET/CT classified the patients as having PMR with a sensitivity/specificity of 86%/63% (Leuven score) and 82%/70% (dichotomous score). Comparing the subgroup of non-PMR with inflammatory diseases to the PMR group demonstrated a specificity of 39%/54% (Leuven/dichotomous score). After 8 weeks of prednisolone treatment, the sensitivity of FDG-PET/CT decreased to 36%/41% (Leuven/dichotomous score), while a short-term prednisolone discontinuation increased the sensitivity to 66%/60%. Conclusion: FDG-PET/CT has limited diagnostic accuracy for differentiating PMR from other inflammatory diseases. If FDG-PET/CT is intended for diagnostic purposes, prednisolone should be discontinued to enhance diagnostic accuracy. Trial registration: ClinicalTrials.gov (NCT04519580). Registered 17th of August 2020.

24 August 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
ANAndreas Wiggers Nielsen
Andreas Wiggers Nielsen
EHEllen-Margrethe Hauge
Ellen-Margrethe Hauge
IHIb Tønder Hansen
Ib Tønder Hansen
BNBerit Dalsgaard Nielsen
Berit Dalsgaard Nielsen
SKSøren Geill Kjær
Søren Geill Kjær
KKKresten Krarup Keller
Kresten Krarup Keller
Objective: The objective was to investigate the incidence of late-onset giant cell arteritis (GCA) within the first year in patients diagnosed with polymyalgia rheumatica (PMR). Methods: In this prospective study, treatment-naïve individuals with a new clinical diagnosis of PMR and without GCA symptoms underwent baseline assessments, including vascular ultrasonography and 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography computed tomography (FDG-PET/CT). To prevent biased inclusion, rapid referral clinics were established for all patients suspected of PMR. Additionally, the patients underwent GCA monitoring during clinical visits at weeks 8 and 10, which involved vascular ultrasonography and FDG-PET/CT scans. After one year, a follow-up visit was performed to confirm the PMR diagnosis and perform vascular ultrasonography. Results: A final PMR diagnosis was assigned to 62 patients, excluding two patients with concurrent subclinical GCA and PMR at baseline, corresponding to a baseline prevalence of subclinical GCA of 3%. During the one-year follow-up, two PMR patients developed late-onset GCA corresponding to an incidence rate of 32 per 1000 person-years. One patient developed GCA 14 weeks after the PMR diagnosis, exhibiting cranial symptoms and positive vascular ultrasonography. The other patient presented with subclinical large vessel GCA at the one-year visit detected with vascular ultrasonography and confirmed by FDG-PET/CT. Conclusion: This study is the first to demonstrate a low incidence rate of late-onset GCA in PMR patients within the first year, employing repeated imaging to exclude GCA at baseline and diagnose GCA during follow-up. Additionally, it provides evidence of a low prevalence of subclinical GCA across the entire PMR population. Trial registration: ClinicalTrials.Gov, NCT04519580

26 July 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
ANAndreas Wiggers Nielsen
Andreas Wiggers Nielsen
KGKornelis S M van der Geest
Kornelis S M van der Geest
IHIb Tønder Hansen
Ib Tønder Hansen
BNBerit Dalsgaard Nielsen
Berit Dalsgaard Nielsen
SKSøren Geill Kjær
Søren Geill Kjær
KKKresten Krarup Keller
Kresten Krarup Keller
Objective: In routine care, clinicians may employ 2-[18F]fluoro-2-deoxy-D-glucose (FDG)-PET/CT to validate their initial clinical diagnosis of PMR. Nevertheless, the diagnostic utility of combining FDG-PET/CT findings with clinical presentation has not been explored. Therefore, this study aimed to investigate whether the diagnostic accuracy for PMR could be enhanced by combining FDG-PET/CT findings with the clinical baseline diagnosis or the 2012 ACR/EULAR clinical classification criteria for PMR. Methods: An investigation and a validation cohort were included from two countries, encompassing 66/27 and 36/21 PMR/non-PMR patients, respectively. The cohorts comprised treatment-naïve patients suspected of PMR, who initially received a clinical baseline diagnosis and underwent FDG-PET/CT scans. The FDG-PET/CT Leuven score was applied to classify patients as either PMR or non-PMR and combined with the clinical baseline diagnosis. Final diagnoses were established through clinical follow-up after 12 or six months in the investigation and validation cohorts, respectively. Results: In the investigation cohort, a clinical baseline diagnosis yielded a sensitivity/specificity of 94%/82%, compared with 78%/70% using the ACR/EULAR criteria. Combining the clinical baseline diagnosis with a positive Leuven score showed a sensitivity/specificity of 80%/93%, compared with 80%/82% for an ACR/EULAR-Leuven score. In the validation cohort, the baseline diagnosis revealed a sensitivity/specificity of 100%/91%, compared with 92%/76% using the ACR/EULAR criteria. Combining FDG-PET/CT with the baseline diagnosis demonstrated a sensitivity/specificity of 83%/95% compared with 89%/81% for the ACR/EULAR-Leuven score. Conclusion: Combining FDG-PET/CT findings with the clinical baseline diagnosis or ACR/EULAR clinical classification criteria can improve the diagnostic specificity for PMR.

25 March 2025 in Rheumatology
Verified
Journal Article
Closed access
CVChristoffer S Våben
Christoffer S Våben
ANAndreas W Nielsen
Andreas W Nielsen
MNMarc K Nielsen
Marc K Nielsen
LMLine T Moll
Line T Moll
CMChristoffer Mørk
Christoffer Mørk
KKKresten K Keller
Kresten K Keller
Objectives: Approximately half of individuals with suspected PMR initiate prednisolone before rheumatological evaluation, but it is unknown if prednisolone reduces the ability to diagnose PMR. This study evaluated the clinical assessment of a PMR diagnosis before and after prednisolone initiation and after short-term prednisolone discontinuation. Methods: Data from a prospective cohort of treatment-naïve patients with PMR (n = 66) and non-PMR (n = 27) were used to create case report forms (CRFs). All patients were assessed at baseline and patients with PMR were reassessed after 8 weeks of prednisolone treatment (n = 57) and after short-term prednisolone discontinuation at week 10 (n = 48). In total, 198 CRFs were created containing patient demographics, current symptoms, physical examination and blood test results. Six rheumatologists, blinded to diagnosis, prednisolone treatment and visit timing, assessed each CRF, rating the probability of a PMR diagnosis from 0 to 10 and classifying them as PMR or non-PMR. Results: At baseline, CRF assessors effectively distinguished PMR from non-PMR, demonstrating median probabilities of PMR of 7.8 and 2.8, respectively, and a sensitivity/specificity of 85.9%/82.7% for the PMR diagnosis. After prednisolone initiation, the median probability of PMR was 1.0 and sensitivity was 3.5%, followed by a median probability of PMR of 2.3 and a sensitivity of 25% after short-term prednisolone discontinuation. Conclusion: This study shows that clinically assessing PMR becomes challenging after prednisolone initiation, and that short-term prednisolone discontinuation does not improve clinical assessment to pre-treatment levels. Consequently, the study supports recommendations of deferring prednisolone initiation until after specialist evaluation in individuals suspected of having PMR.